Facility Volume and Survival in Nasopharyngeal Carcinoma
- PMID: 29100787
- DOI: 10.1016/j.ijrobp.2017.09.038
Facility Volume and Survival in Nasopharyngeal Carcinoma
Abstract
Introduction: Definitive treatment of nasopharyngeal carcinoma (NPC) is challenging owing to its rarity, complicated regional anatomy, and the intensity of therapy. In contrast to other head and neck cancers, the effect of facility volume has not been well described for NPC.
Methods and materials: The National Cancer Database was queried for patients with stage II-IVB NPC diagnosed from 2004 to 2014 and treated with definitive radiation. Patients with incomplete staging, unknown receipt or timing of treatment, unknown follow-up duration, incomplete socioeconomic information, or treatment outside the reporting facility were excluded. High-volume facilities (HVFs) were defined as the top 5% of facilities according to the annual facility volume.
Results: The present analysis included 3941 NPC patients treated at 804 facilities with a median follow-up duration of 59.4 months, including 1025 patients (26.0%) treated at HVFs. Treatment at HVFs was associated with significantly improved overall survival (OS) on multivariable analysis (hazard ratio 0.79, 95% confidence interval 0.69-0.90; P=.001). In propensity score-matched cohorts, 5-year OS was 69.1% versus 63.3% at HVFs versus lower volume facilities (LVFs), respectively (P=.003). Similar results were seen when facility volume was analyzed as a continuous variable. The effect of facility volume on survival varied by academic status (P=.002 for interaction). At academic centers, the propensity score-matched cohorts had 5-year OS of 71.4% compared with 62.4% (P<.001) at HVFs and LVFs, respectively. In contrast, the 5-year OS was 63.5% versus 67.9% (P=.68) in propensity score-matched patients at nonacademic HVFs and LVFs.
Conclusions: Treatment at HVFs was associated with improved OS for patients with NPC, with the effect exclusively seen at academic centers.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.Cancer. 2017 Oct 15;123(20):3933-3942. doi: 10.1002/cncr.30843. Epub 2017 Jun 22. Cancer. 2017. PMID: 28640546
-
Impact of treating facilities' type and volume in patients with major salivary gland cancer.Laryngoscope. 2019 Oct;129(10):2321-2327. doi: 10.1002/lary.27844. Epub 2019 Jan 30. Laryngoscope. 2019. PMID: 30698823
-
The Impact of Academic Facility Type and Case Volume on Survival in Patients Undergoing Curative Radiation Therapy for Muscle-Invasive Bladder Cancer.Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):851-857. doi: 10.1016/j.ijrobp.2017.11.040. Epub 2017 Dec 5. Int J Radiat Oncol Biol Phys. 2018. PMID: 29485062
-
Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):683-90. doi: 10.1016/j.ijrobp.2015.12.008. Epub 2015 Dec 14. Int J Radiat Oncol Biol Phys. 2016. PMID: 26972640
-
Trimodality therapy for esophageal cancer at high volume facilities is associated with improved postoperative outcomes and overall survival.Dis Esophagus. 2019 Apr 1;32(4):doy067. doi: 10.1093/dote/doy067. Dis Esophagus. 2019. PMID: 30052835
Cited by
-
Integrative analysis of miRNAs-mRNAs reveals that miR-182 up-regulation contributes to proliferation and invasion of nasopharyngeal carcinoma by targeting PTEN.Aging (Albany NY). 2020 Jun 15;12(12):11568-11578. doi: 10.18632/aging.103316. Epub 2020 Jun 15. Aging (Albany NY). 2020. PMID: 32541092 Free PMC article.
-
Nationwide changes in radiation oncology travel and location of care before and during the COVID-19 pandemic.Radiat Oncol J. 2023 Jun;41(2):108-119. doi: 10.3857/roj.2023.00164. Epub 2023 Jun 22. Radiat Oncol J. 2023. PMID: 37403353 Free PMC article.
-
Single community-based institutional series of stereotactic body radiation therapy (SBRT) for treatment of liver metastases.J Gastrointest Oncol. 2019 Apr;10(2):330-338. doi: 10.21037/jgo.2018.11.03. J Gastrointest Oncol. 2019. PMID: 31032102 Free PMC article.
-
Precision Medicine for Nasopharyngeal Cancer-A Review of Current Prognostic Strategies.Cancers (Basel). 2024 Feb 24;16(5):918. doi: 10.3390/cancers16050918. Cancers (Basel). 2024. PMID: 38473280 Free PMC article. Review.
-
CircRNA ZNF609 Knockdown Suppresses Cell Growth via Modulating miR-188/ELF2 Axis in Nasopharyngeal Carcinoma.Onco Targets Ther. 2020 Mar 23;13:2399-2409. doi: 10.2147/OTT.S234230. eCollection 2020. Onco Targets Ther. 2020. PMID: 32273713 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources